Skip to content

Study · Systematic review · 2024

5 results

Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis.

Stefanou MI, Theodorou A, Malhotra K, Aguiar de Sousa D, Katan M, Palaiodimou L, Katsanos AH, Koutroulou I, Lambadiari V, Lemmens R, Giannopoulos S, Alexandrov AV, Siasos G, Tsivgoulis G

European stroke journal23 Feb 2024Cited by 51 (Europe PMC)

PMID38400569 (opens in a new tab)PMCIDPMC11418422 (opens in a new tab)DOI10.1177/23969873241234238 (opens in a new tab)PepBankPUB-38400569
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, the reductions in MACE and mortality did not differ between GLP-1 RAs and GIP/GLP-1 RAs such as tirzepatide.

    In plain wordsIn adults with type 2 diabetes, tirzepatide and GLP-1 drugs lowered heart events and deaths to a similar degree.

    Peptide
    Tirzepatide
    Outcome
    No significant changeMACE and mortality: GIP/GLP-1 RA versus GLP-1 RAs
    Study

    n: not reported in source

    Comparator
    GLP-1 receptor agonists
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    without differences between GLP-1 versus GIP/GLP-1 RAs.
    1 context sentence
    Summary · context
    Thirteen RCTs (9 and 4 on GLP-1 RAs and tirzepatide, respectively) comprising 65,878 T2DM patients were included.

Studies that did not test the peptide alone4

In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Tirzepatide.

  1. 02HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, pooled GLP-1 RAs and the GIP/GLP-1 RA tirzepatide reduced MACE versus placebo.

    In plain wordsIn adults with type 2 diabetes, GLP-1 drugs including tirzepatide lowered major heart events compared with placebo.

    Peptide
    Tirzepatide
    Outcome
    DecreaseMajor adverse cardiovascular events (MACE)
    Study

    n = 65,878

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular

    Measurements

    OR
    0.87 ratio
    MACE, pooled GLP-1 RAs and GIP/GLP-1 RAs

    Source sentences

    Summary
    Compared to placebo, GLP-1RAs or GIP/GLP-1 RAs reduced MACE (OR: 0.87; 95% CI: 0.81-0.94; p I2 = 37%)
    1 context sentence
    Summary · context
    Thirteen RCTs (9 and 4 on GLP-1 RAs and tirzepatide, respectively) comprising 65,878 T2DM patients were included.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  2. 03HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, pooled GLP-1 RAs and tirzepatide reduced all-cause mortality versus placebo.

    In plain wordsIn adults with type 2 diabetes, GLP-1 drugs including tirzepatide lowered deaths from any cause compared with placebo.

    Peptide
    Tirzepatide
    Outcome
    DecreaseAll-cause mortality
    Study

    n = 65,878

    Comparator
    Placebo
    Outcome group
    Mortality · Cardiovascular

    Measurements

    OR
    0.88 ratio
    all-cause mortality

    Source sentences

    Summary
    all-cause mortality (OR: 0.88; 95% CI: 0.82-0.96; p I2 = 21%)
    1 context sentence
    Summary · context
    Thirteen RCTs (9 and 4 on GLP-1 RAs and tirzepatide, respectively) comprising 65,878 T2DM patients were included.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  3. 04HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, pooled GLP-1 RAs and tirzepatide reduced cardiovascular mortality versus placebo.

    In plain wordsIn adults with type 2 diabetes, GLP-1 drugs including tirzepatide lowered heart-related deaths compared with placebo.

    Peptide
    Tirzepatide
    Outcome
    DecreaseCardiovascular mortality
    Study

    n = 65,878

    Comparator
    Placebo
    Outcome group
    Mortality · Cardiovascular

    Measurements

    OR
    0.88 ratio
    cardiovascular mortality

    Source sentences

    Summary
    cardiovascular-mortality (OR: 0.88; 95% CI: 0.80-0.96; p I2 = 14%)
    1 context sentence
    Summary · context
    Thirteen RCTs (9 and 4 on GLP-1 RAs and tirzepatide, respectively) comprising 65,878 T2DM patients were included.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  4. 05HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, GLP-1 RAs and GIP/GLP-1 RAs were not associated with fatal or nonfatal myocardial infarction.

    In plain wordsIn adults with type 2 diabetes, GLP-1 drugs including tirzepatide showed no link with heart attacks.

    Peptide
    Tirzepatide
    Outcome
    No significant changeFatal or nonfatal myocardial infarction
    Study

    n = 65,878

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular

    Source sentences

    Summary
    There was no association between GLP-1RAs or GIP/GLP-1 RAs and fatal or nonfatal myocardial infarction.
    1 context sentence
    Summary · context
    Thirteen RCTs (9 and 4 on GLP-1 RAs and tirzepatide, respectively) comprising 65,878 T2DM patients were included.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.